StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Earnings

Iovance Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$121.47M
+80.1% on a year earlier
EPS, Q3 FY2026
-$0.05
-$0.25 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Iovance Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$121.47M+80.1%-$0.05Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$99.31M–-$0.11Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026before the open$86.71M+17.7%-$0.18Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$67.46M–-$0.25Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025after the close$73.70M+14640.0%-$0.26Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close$31.10M+12967.2%-$0.34Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$700.00K–-$0.42Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Iovance Biotherapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total product revenueFY2026$410.00M – $420.00M–NewNov 5, 2026
total revenue guidanceFY2026$350.00M – $370.00M$350.00M – $370.00MReaffirmedAug 6, 2026

Guidance vs results

The last range Iovance Biotherapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q2 FY2026Revenue$86.00M – $88.00M$99.31MAbove range

Guidance history

Every forecast Iovance Biotherapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026total product revenueFY2026$410.00M – $420.00MNew
Aug 6, 2026total revenue guidanceFY2026$350.00M – $370.00MReaffirmed
May 7, 2026Total product revenueFY2026$350.00M – $370.00MNew
May 7, 2026Total product revenueQ2 FY2026$86.00M – $88.00MNew
May 7, 2026U.S. Amtagvi revenueQ2 FY2026$79.00M – $81.00MLowered
Nov 6, 2025r evenueFY2025$250.00M – $300.00MNew
Feb 27, 2025total product revenueFY2025$450.00M – $475.00MReaffirmed
Aug 8, 2024Total product revenueQ3 FY2024$53.00M – $55.00MNew
Aug 8, 2024Total product revenueFY2024$160.00M – $165.00MNew
Aug 8, 2024total product revenueFY2025$450.00M – $475.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Iovance Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. News
  2. Results
  3. News
  4. News
  5. News
  6. News
  7. Results
  8. News
  9. News
  10. Results
  11. Results
  12. Results
  13. News
  14. Results
  15. News

See a number that looks wrong?